# US 2016/0250284 A1 · Methods for treating restenosis using annexin a5

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250284 A1
- Document ID: US20160250284A1
- Status: Published application
- Kind: A1
- Application number: 15/058,068
- Filed: 2016-03-01
- Published: 2016-09-01
- Earliest claimed: 2008-02-22
- Assignees: Annexin Pharmaceuticals AB
- Applicants: Annexin Pharmaceuticals AB
- Inventors: Knut PETTERSSON; Johan Frostegård; Ola CAMBER
- Web page: https://patentgrep.com/patent/US20160250284A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 27/3625: {Vascular tissue, e.g. heart valves}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 33/0011: {Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4721: {Lipocortins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/42: Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analogue or variant thereof, and a method of making such a stent.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method for the treatment of restenosis, wherein the restenosis is caused by neointima formation or neointimal thickening, in a patient with restenosis, wherein the method comprises:
administering a therapeutically effective amount of an active agent to the patient, wherein the active agent is selected from the group consisting of an Annexin A5 polypeptide, a dimer of the Annexin A5 polypeptide, the Annexin A5 polypeptide that has been PEGylated, and a dimer of the Annexin A5 polypeptide that has been PEGylated; and
wherein the Annexin A5 polypeptide consists of an amino acid sequence which has more than 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 and which binds to phosphatidylserine on a biological membrane to a level that is at least 80% of that displayed by human Annexin A5 having the sequence of SEQ ID NO:1 under the same conditions.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the restenosis is associated to a bypass graft.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the restenosis is associated to a catheter based intervention.

### Claim 23 (depends on 20)

The method of claim 20, wherein the restenosis is associated with the implantation of a stent.

### Claim 24 (depends on 20)

The method of claim 20, wherein the therapeutically effective amount of the active agent is administered parenterally, intravenously, intra-arterially, intra-peritoneally, intra-muscularly, subcutaneously or is administered locally from a drug eluting stent.

### Claim 25 (depends on 20)

The method of claim 20, wherein the active agent is administered in conjunction with a thrombolytic therapeutic.

### Claim 26 (depends on 20)

The method of claim 20, wherein the Annexin A5 polypeptide is selected from the group consisting of:
a) human Annexin A5 consisting of the sequence of SEQ ID NO:1;
b) a dimer of human Annexin A5 consisting of the sequence of SEQ ID NO1;
c) human Annexin A5 consisting of the sequence of SEQ ID NO:1 that has been PEGylated; and
d) a dimer of human Annexin A5 consisting of the sequence of SEQ ID NO:1 that has been PEGylated.

### Claim 27 (depends on 25)

The method of claim 25 wherein the thrombolytic therapeutic is selected from the group consisting of aspirin, clopidogrel, triclopidine, tissue plasminogen activator, urokinase, and streptokinase.

### Claim 28 (depends on 20)

The method of claim 20, wherein the administering of the therapeutically effective amount of an active agent to the patient is for a period selected from the group consisting of at least 2 weeks, and at least 1 month.

### Claim 29 (depends on 28)

The method of claim 28, wherein the administering is for a period of at least 2 months to at least 10 years.

### Claim 30 (depends on 20)

The method of claim 20, wherein the Annexin A5 polypeptide consists of an amino acid sequence which has more than 99% sequence identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 31 (depends on 20)

The method of claim 20, wherein the Annexin A5 polypeptide consists of the amino acid sequence of SEQ ID NO:1.

### Claim 32 (depends on 20)

The method of claim 20, wherein the method protects against worsening of the restenosis, or the restenosis worsens more gradually or to a reduced extent in the patient.

### Claim 33 (depends on 20)

The method of claim 20, wherein the administering of the therapeutically effective amount of an active agent to the patient is for a period of at least 2 months.

### Claim 34 (depends on 20)

The method of claim 20, wherein the administering of the therapeutically effective amount of an active agent to the patient is for a period of at least 6 months.

### Claim 35 (depends on 20)

The method of claim 20, wherein the administering of the therapeutically effective amount of an active agent to the patient is for a period of at least 1 year.

### Claim 36 (depends on 20)

The method of claim 20, wherein the administering of the therapeutically effective amount of an active agent to the patient is for a period of at least 2 years.

### Claim 37 (depends on 20)

The method of claim 20, wherein the method comprises administering of the therapeutically effective amount of an active agent to the patient for a period of at least 5 years.

### Claim 38 (depends on 20)

The method of claim 20, wherein the administering of the therapeutically effective amount of an active agent to the patient is for a period of at least 10 years.
